Clinical Trial SuccessStrong statistical significance in Ph. 2 results and CLDX replicating Ph. 2’s design in Ph. 3 while adding loading doses give confidence that barzo can succeed in Ph. 3 and demonstrate best-in-class efficacy.
Efficacy And SafetyCLDX's lead asset barzolvolimab remains the clear leader in this space, having demonstrated substantially more robust efficacy with a well-tolerated safety profile.
Long-term DurabilityThe new 52-week data demonstrate barzo has long-term durability, is effective regardless of omalizumab experience, and critically, maintains a manageable safety and tolerability profile.